# OnCo record idea-adjuvant-selection-rcc (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-adjuvant-selection-rcc/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-adjuvant-selection-rcc" ;
  schema:name "Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)"@en ;
  schema:description "Adjuvant immunotherapy after kidney cancer surgery is given to everyone at high pathological risk although most would never relapse, so a year of toxicity is spread across the whole group to help a minority. A biomarker such as CAIX PET or kidney-specific tumour DNA could pick out the few who need it."@en ;
  schema:url <https://onco.cc/ideas/idea-adjuvant-selection-rcc/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03142334>, <https://clinicaltrials.gov/study/NCT05239728> ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/caix-pet/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/belzutifan/> ;
  onco:trials <https://onco.cc/trials/keynote-564/>, <https://onco.cc/trials/litespark-022/>, <https://onco.cc/trials/imvigor011/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-564-nejm-2021/> .